Neuromelanin can protect against iron‐mediated oxidative damage in system modeling iron overload of brain aging and Parkinson’s disease
暂无分享,去创建一个
Alberto Albertini | Tadeusz Sarna | T. Sarna | L. Casella | A. Żądło | L. Zecca | F. Zucca | A. Albertini | Fabio A. Zucca | Luigi Zecca | Luigi Casella | C. Bellei | Grzegorz Szewczyk | M. Engelen | G. Szewczyk | M. Zaręba | Andrzej Zadlo | Chiara Bellei | Mireille Engelen | Mariusz Zareba | Mireille Engelen | M. Zarȩba
[1] F. García-Cánovas,et al. Improvement of a Continuous Spectrophotometric Method for Determining the Monophenolase and Diphenolase Activities of Mushroom Polyphenol Oxidase , 1997 .
[2] D. Sulzer,et al. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease , 2007, Trends in Neurosciences.
[3] B. Halliwell,et al. 1 Iron toxicity and oxygen radicals , 1989 .
[4] D. Sulzer,et al. Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour , 2001, Molecular pathology : MP.
[5] Rabi Tawil,et al. Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights. , 2005, Journal of neuropathology and experimental neurology.
[6] T. Shima,et al. Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study. , 1997, Free radical biology & medicine.
[7] G. Deuschl,et al. Activation of microglia by human neuromelanin is NF‐κB‐dependent and involves p38 mitogen‐activated protein kinase: implications for Parkinson's disease , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[8] G. Edwards,et al. The surface oxidation potential of human neuromelanin reveals a spherical architecture with a pheomelanin core and a eumelanin surface , 2006, Proceedings of the National Academy of Sciences.
[9] H. Schipper. Brain iron deposition and the free radical-mitochondrial theory of ageing , 2004, Ageing Research Reviews.
[10] Peter T. Lansbury,et al. Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct , 2001, Science.
[11] D. Radice,et al. Iron and Other Metals in Neuromelanin, Substantia Nigra, and Putamen of Human Brain , 1994, Journal of neurochemistry.
[12] E. Hirsch,et al. Neuromelanin associated redox‐active iron is increased in the substantia nigra of patients with Parkinson's disease , 2003, Journal of neurochemistry.
[13] T. Sarna,et al. The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems. , 1995, Biochimica et biophysica acta.
[14] P. Arosio,et al. Characterization of the l-ferritin variant 460InsA responsible of a hereditary ferritinopathy disorder , 2006, Neurobiology of Disease.
[15] A. Graybiel,et al. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease , 1988, Nature.
[16] D. Selkoe,et al. Dopamine covalently modifies and functionally inactivates parkin , 2005, Nature Medicine.
[17] H. Schipper. Glial HO-1 expression, iron deposition and oxidative stress in neurodegenerative diseases , 1999, Neurotoxicity Research.
[18] Wade K. Smith,et al. Disease‐specific patterns of locus coeruleus cell loss , 1992, Annals of neurology.
[19] J. Langston,et al. Iron‐mediated bioactivation of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) in glial cultures , 1995, Glia.
[20] R. Silber,et al. A spectrophotometric assay for dehydroascorbate reductase. , 1983, Analytical biochemistry.
[21] P. Riederer,et al. Structural Characteristics of Human Substantia Nigra Neuromelanin and Synthetic Dopamine Melanins , 2000, Journal of neurochemistry.
[22] Subramanian Rajagopalan,et al. Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo A Novel Therapy for Parkinson's Disease , 2003, Neuron.
[23] J. Langston,et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine exposure , 1999, Annals of neurology.
[24] J. Segura-Aguilar,et al. Aminochrome as a preclinical experimental model to study degeneration of dopaminergic neurons in Parkinson’s disease , 2007, Neurotoxicity Research.
[25] E. Hirsch,et al. Blood vessels change in the mesencephalon of patients with Parkinson's disease , 1999, The Lancet.
[26] P. Riederer,et al. Iron-binding characteristics of neuromelanin of the human substantia nigra. , 2003, Biochemical pharmacology.
[27] D. Sulzer,et al. Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics , 2003, Trends in Neurosciences.
[28] N. Turro,et al. Amyloid β and neuromelanin—Toxic or protective molecules? The cellular context makes the difference , 2006, Progress in Neurobiology.
[29] K. Jellinger,et al. Iron‐Melanin Complex in Substantia Nigra of Parkinsonian Brains: An X‐Ray Microanalysis , 1992, Journal of neurochemistry.
[30] Alberto Gatti,et al. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[31] B. Bergamasco,et al. EPR investigations of the iron domain in neuromelanin. , 1997, Biochimica et biophysica acta.
[32] H. M. Swartz,et al. Interaction of neuromelanin and iron in substantia nigra and other areas of human brain , 1996, Neuroscience.
[33] K. Jellinger,et al. The Neuropathologic Basis of Different Clinical Subgroups of Parkinson's Disease , 1991, Journal of neuropathology and experimental neurology.
[34] C. Morris,et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease , 2001, Nature Genetics.
[35] L. Casella,et al. Tyrosinase-catecholic substrates in Vitro model: kinetic studies on the o-quinone/o-semiquinone radical formation☆ , 1997 .
[36] J. Connor,et al. Iron, brain ageing and neurodegenerative disorders , 2004, Nature Reviews Neuroscience.
[37] O. Rascol,et al. Intracellular Ferritin Accumulation in Neural and Extraneural Tissue Characterizes a Neurodegenerative Disease Associated with a Mutation in the Ferritin Light Polypeptide Gene , 2004, Journal of neuropathology and experimental neurology.
[38] S. Ito,et al. Interaction of Human Substantia Nigra Neuromelanin with Lipids and Peptides , 2000, Journal of neurochemistry.
[39] K. Vrana,et al. Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase , 1998, Journal of neuroscience research.
[40] B. Bergamasco,et al. Modifications of the iron–neuromelanin system in Parkinson's disease , 2006, Journal of neurochemistry.
[41] K. Wakamatsu,et al. The structure of neuromelanin as studied by chemical degradative methods , 2003, Journal of neurochemistry.
[42] J. Loike,et al. Macrophages adhere to glucose-modified basement membrane collagen IV via their scavenger receptors. , 1994, The Journal of biological chemistry.
[43] M. Rice. Ascorbate regulation and its neuroprotective role in the brain , 2000, Trends in Neurosciences.
[44] J. B. Justice,et al. Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter , 2001, Journal of neurochemistry.
[45] R. Floyd,et al. Use of salicylate with high pressure liquid chromatography and electrochemical detection (LCED) as a sensitive measure of hydroxyl free radicals in adriamycin treated rats. , 1986, Journal of free radicals in biology & medicine.
[46] T. Sarna,et al. Antioxidant action of neuromelanin: the mechanism of inhibitory effect on lipid peroxidation. , 1995, Archives of biochemistry and biophysics.
[47] C. Marsden,et al. Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease , 1989, Journal of neurochemistry.
[48] Alberto Albertini,et al. The neuromelanin of human substantia nigra: physiological and pathogenic aspects. , 2004, Pigment cell research.